logo
Plus   Neg
Share
Email

Merck KGaA Q3 Net Profit Edges Up; Lifts FY19 Forecast - Quick Facts

German science and technology company Merck KGaA (MKGAY.PK) reported Thursday that its third-quarter net income attributable to shareholders increased 0.8 percent to 343 million euros from last year's 340 million euros.

Earnings per share were 0.79 euro, up 1.3 percent from 0.78 euro a year ago. Earnings per share pre were 1.35 euros, compared to 1.32 euros last year.

EBITDA grew 16.7 percent from last year to 1.07 billion euros. EBITDA pre went up 15.4 percent to 1.11 billion euros.

Group net sales rose 8.1 percent to 4.05 billion euros from last year's 3.75 billion euros, driven by double-digit growth in Healthcare and Life Science.

Group organic sales growth amounted to 5.7 percent.

Looking ahead for fiscal 2019, the company said it raised forecast for EBITDA pre and sales following the closing of the Versum Materials acquisition.

Group EBITDA pre for 2019 is now expected between 4.23 billion euros and 4.43 billion euros, compared to previous view between 4.15 billion euros and 4.35 billion euros. This is higher than last year's 3.80 billion euros.

Overall, net sales are forecast to be between 15.7 billion euros and 16.3 billion euros now, compared to earlier forecast of 15.3 billion euros to 15.9 billion euros. In 2018, net sales were 14.836 billion euros.

Merck continues to expect a strong organic increase in EBITDA pre, and a moderate organic net sales increase of 3 percent to 5 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT